{
  "paper_id": "PMC8029445",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8029445/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Top 21 countries by number of COVID-19 candidate\nvaccines in the development pipelines.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/a8dbfb8957ff/oc1c00120_0001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Distribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c60ec24d90cb/oc1c00120_0002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Distribution of COVID-19 vaccine candidates\nin clinical trials among top seven countries regarding the trial stages\nand vaccine platforms.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/20fd07973a4b/oc1c00120_0003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Vaccine platforms and their ways of producing immunogen in cells.\n(A) Inactivated vaccine results in a broader spectrum of antigens\nwhen it is taken up and broken down by cells. (B) Protein-based vaccine\nproduces a more focused response to a targeted antigen when it is\ntaken up and processed into multiple epitopes by cells. (C) Viral\nvector vaccine delivers antigen-encoding DNA to cells and enhances\nthe inflammatory response and immunity. (D) Nucleic acid vaccine enters\ncells and serves as the transcriptional/translational template for\nprotein antigen synthesis.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/6b6e5c58c327/oc1c00120_0004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "Schematic illustration\nof an mRNA molecule with the structural elements.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0cbf4ded9353/oc1c00120_0005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "Chemical structures of uridine, pseudouridine, and N1-methyl-pseudouridine.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c364fb394aa8/oc1c00120_0006.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Figure 7.",
      "caption": "Suggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4eeca9ccbfb7/oc1c00120_0007.jpg"
    },
    "figure_8": {
      "figure_number": "Figure 8",
      "title": "Figure 8.",
      "caption": "COVID-19 vaccine-related\njournal article publications classified according to country (A) and\norganization (B); values are presented as number per thousand (‰).\nThe increase in color intensity reflects the increase in the number\nof publications.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig8",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_8.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/4d4a60bced89/oc1c00120_0008.jpg"
    },
    "figure_9": {
      "figure_number": "Figure 9",
      "title": "Figure 9.",
      "caption": "Distribution\nof COVID-19 vaccine-related journal publications in different research\nareas.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig9",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_9.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/0d3a7bce6754/oc1c00120_0009.jpg"
    },
    "figure_10": {
      "figure_number": "Figure 10",
      "title": "Figure 10.",
      "caption": "Distribution of COVID-19-related\njournal publications among vaccine platforms.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig10",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_10.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/15f7c20395c9/oc1c00120_0010.jpg"
    },
    "figure_11": {
      "figure_number": "Figure 11",
      "title": "Figure 11.",
      "caption": "COVID-19 cross-protection by other vaccines. Numbers of documents\nare next to the vaccine names. In the inset pie-charts for BCG, influenza,\nand MMR, “Yes” indicates documents suggesting cross-protection,\n“No” indicates documents suggesting there is no cross-protection;\n“?” indicates documents which are inconclusive. “Other\nvaccines” include encephalitis, hepatitis, Newcastle disease,\nrotavirus, polio, and other routine childhood vaccines.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig11",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_11.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/f717fea009fa/oc1c00120_0011.jpg"
    },
    "figure_12": {
      "figure_number": "Figure 12",
      "title": "Figure 12.",
      "caption": "Structure\nof the chemically modified cyclic dinucleotide adjuvant from patent\napplication CN111956797A. Guanine nucleobase is shown in the boxes.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig12",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8029445/images/figure_12.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/526e/8155458/c5873d5802fc/oc1c00120_0012.jpg"
    }
  },
  "claims": [
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "By the end of February 2021, more than 40 countries and regions were\nworking on developing COVID-19 vaccines, and at least half of these\ncountries have had one or more vaccines in clinical trials, based\non the analysis of vaccine development data from the World Health\nOrganization (WHO).22 As shown in Figure 1, the United States leads many other countries and\nregions in the number of both clinical (17) and preclinical (39) vaccine\ncandidates.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Figure 2 illustrates the distribution of various\nCOVID-19 vaccine candidates among different platforms.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Figure 3 lists the top seven countries according\nto the number of COVID-19 vaccine candidates in clinical trial.",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Vaccine Platforms\nMultiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Multiple vaccine platforms have been explored for COVID-19 vaccine\ndevelopment as each vaccine platform has unique advantages and disadvantages\n(Table 1 and Figure 4).22 It is very likely that the world will need more than one\ntype of approved vaccine to combat this pandemic with assurance of\nbroad target population coverage, production quantities, and storage\nand transportation requirements on top of vaccine safety and effectiveness.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Because it is inherently safe and uses well-established\ntechniques of protein purification, these vaccines comprise the largest\ncategory in COVID-19 vaccine development, as shown in Figure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A total of 24 COVID-19 protein subunit vaccine candidates have entered\nclinical trials, including those by Novavax, Anhui Zhifei Longcom\nBiopharmaceutical, Kentucky Bioprocessing, and Sanofi/GlaxoSmithKline\n(GSK) (Table 3), while\n68 more are in preclinical evaluation (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition,\nwithout a cap, the IVT mRNA would be recognized as foreign RNA by\nthe host immune system through a mechanism mediated by Toll-like receptors\n7/8.79 Capping of IVT mRNA would prevent\nits recognition by the host immune system and reduce immunogenicity\ncaused by mRNA molecule itself.77,80\nThe elongated\npoly (A) tail at the 3′ end is important for the stability\nand subsequent translation of mRNA.81 Incorporation\nof UTR sequences enhances mRNA half-life and translation efficiency.82 For example, incorporating a human β-globin\nUTR to both 5′- and 3′-UTR of the mRNA has been shown\nto enhance the stability and translational efficiency,83 whereas insertion of an α-globin UTR to\nthe 3′-UTR region increased the mRNA stability.84 Both 3′- and 5′-UTR regions can\nalso inhibit decapping and degradation of mRNA.83,84 As such, sequence modifications in both 5′- and 3′-UTRs\nhave been explored to enhance the mRNA vaccine functionality.85\nIn addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Like mammalian\nmRNA, mRNA vaccines produced by in vitro transcription\n(IVT) contain an open reading frame (ORF) flanked by 5′ and\n3′ untranslated regions (UTRs), a 5′-cap, and a 3′\npolyadenylation (poly(A)) tail, as shown in Figure 5.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "In addition, unmodified IVT mRNA sequences\ncan stimulate Toll-like receptors (TLRs) and activate the innate immune\nsystem.86 To reduce immunogenicity of the\nIVT mRNA, a variety of modified nucleotides have been introduced into\nthe ORF region.86,87 For instance, designed incorporation\nof pseudouridine (ψ) (Figure 6) has been shown to reduce immunogenicity and improve\ntranslation.88 Additionally, mRNA containing\nN1-methyl-pseudouridine (m1ψ) (Figure 6) exhibited an increase\nin translational efficiency.89 Recent studies\nhave shown that this increase is related to N1-methyl-pseudouridine\ninduced enhancement of ribosome recycling to the same mRNA.90.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "It has been suggested that the delivery efficacy of the cationic lipids\ncorrelates with their ability to modulate the phase behavior of the\nbiomembrane lipids, specifically to induce formation of nonlamellar\nlipid phases.92,93\nFigure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nSuggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Draped by positively charged lipids, the mRNA is more\nstable and resilient to RNase degradation and forms self-assembled\nnanoparticles (Figure 7).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "The compositions of the\nlipid nanoparticles of the Pfizer/BioNTech and Moderna mRNA vaccines\nare similar: ionizable cationic lipid, PEGylated lipid, cholesterol,\nand the phospholipid distearoylphosphatidylcholine (DSPC) as a helper\nlipid,11,12,94−96 as shown in Figure 7.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Figure 8 depicts the relative number of COVID-19\nvaccine-related papers (articles per thousand) classified by country\n(A) and organization (B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "The University of California, University\nof Oxford, and the National Institutes of Health (USA) have published\nthe highest number of documents on COVID-19 vaccine-related research\n(Figure 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nDistribution\nof COVID-19 vaccine-related journal publications in different research\nareas.Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "According to a Mayo Clinic research study, various\nvaccines, from influenza to measles, etc., appear to provide partial\nprotection against COVID-19.115 The exact\nmechanisms underlying the beneficial off-target effects of the vaccines\nare not well understood, but it is believed that vaccines induce metabolic\nand epigenetic changes that enhance the innate immune response to\ninfections, a process termed trained immunity.116,117\nThose documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "Evidence indicates\nthat countries with recent vaccination campaigns against MMR (measles,\nmumps, rubella) have fewer COVID-19 deaths.125 Sequence homology has been identified between the SARS-CoV-2 S glycoprotein\nand both the measles virus fusion (F1) glycoprotein and the rubella\nvirus envelope (E1) glycoprotein, suggesting that the MMR vaccine\nmay mitigate COVID-19 spread and severity.125,126\nFigure 11.",
      "figure_references": [
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "As shown in Figure 9, about 15% of the published\njournal articles have been devoted to exploration of various vaccine\nplatforms.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Those documents related to vaccine\nplatforms were further analyzed to reveal the percentage of publications\nassociated with each platform (Figure 10).",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        },
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As Figure 9 shows, there is a significant number of publications regarding vaccine\ncross-protection.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Those documents related to COVID-19 cross-protection by other\nvaccines, as shown in Figure 9, were further analyzed to illustrate the distribution of\npublications per existing vaccines (Figure 11).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        },
        {
          "figure_number": "Figure 11",
          "panel": "",
          "figure_key": "figure_11"
        }
      ]
    },
    {
      "sentence": "SARS-CoV-2 Mutations and Vaccine Effectiveness\nPrevious studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Previous studies have shown that RNA viruses, especially those\nresponsible for respiratory diseases, pose a significant threat to\nglobal health.127 The spread of these RNA\nviruses among the population may select for mutations that change\nthese viruses’ pathogenesis, virulence, and transmissibility,\nor a combination of these.128 As Figure 9 shows, there are a significant number of publications regarding SARS-CoV-2 mutations\nin the context of vaccine development.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    },
    {
      "sentence": "The structure of a representative compound is\nshown in Figure 12, in which the guanine nucleobase is in the shaded areas.",
      "figure_references": [
        {
          "figure_number": "Figure 12",
          "panel": "",
          "figure_key": "figure_12"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 12,
    "claims_count": 216,
    "images_downloaded": 12,
    "tables_filtered": 394
  }
}